Anti-Aging Drug Discovery Targeting MDM2

Aging is a complex biological process characterized by a gradual decline in cellular function and increased susceptibility to diseases. Mouse double minute 2 homolog (MDM2) is a negative regulator of p53. The interaction between MDM2 and p53 is critical in determining whether a cell will undergo senescence or continue to divide. As organisms age, MDM2 expression increases, leading to increased p53 degradation and a lowering of cellular senescence threshold, contributing to the aging process.

Fig. 1 Proper regulation (balance) of p53 by MDM2 is needed for normal aging. Aberrant regulation can lead to tumorigenic, accelerated aging, or lethal phenotypes. (Wu D and Prives C, 2017)

At CD BioSciences, we are dedicated to unraveling the molecular mechanisms of aging to help clients develop innovative anti-aging therapeutics. We are focused on advancing anti-aging drug discovery by targeting the MDM2 signaling pathway, a pivotal regulator in cellular aging and senescence.

How Do We Develop Anti-Aging Drugs Targeting MDM2?

CD BioSciences employs bioinformatics tools and high-throughput screening to identify small molecules and biologics that can specifically inhibit the MDM2 pathway. Our cell-based assays evaluate the efficacy of drugs targeting the MDM2 pathway in restoring p53 activity. Furthermore, we help clients analyze the impact of these drugs on aging-related phenotypes, including lifespan, behaviors, and key biomarkers, in diverse models such as mice, worms, Drosophila, and zebrafish. CD BioSciences also provides comprehensive preclinical evaluation services, rigorously assessing the safety and efficacy of these novel drugs.

Anti-Aging Drug Categories Targeting MDM2 We Can Develop

We help clients develop small molecule inhibitors and peptide-based therapeutics that inhibit the MDM2 signaling pathway. CD BioSciences also offers gene therapy approaches to modulate the MDM2 pathway. For RNA interference (RNAi), we use small interfering RNA (siRNA) molecules to reduce the expression of MDM2, leading to p53 stabilization and activation. We offer services to modify the MDM2 genes directly in aging cells.

Targeting MDM2 in Knee Osteoarthritis

Knee osteoarthritis (OA) is a common age-related disease characterized by cartilage degeneration and joint inflammation. The MDM2-p53 pathway has been implicated in the pathogenesis of OA, making it an attractive target for therapeutic intervention. CD BioSciences helps clients investigate the potential of drugs targeting the MDM2 pathway to mitigate the progression of knee OA by reducing cellular senescence and promoting cartilage regeneration. Our preclinical services include the use of in vitro cell models and in vivo animal models to assess the efficacy and safety of these drugs in knee OA.

Targeting the MDM2 signaling pathway represents a promising strategy in the pursuit of effective anti-aging therapeutics. CD BioSciences works with our clients to advance this field through innovative drug discovery services that address the complexities of aging. We aim to help clients develop innovative therapeutics that enhance cellular longevity and resilience. If you are interested in our services, please feel free to contact us or make an online inquiry.

Reference

1. Wu D, Prives C. Relevance of the p53-MDM2 axis to aging. Cell Death Differ, 2018, 25 (1): 169-179.